Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
Xiuning LeRobin CornelissenMarina-Chiara GarassinoJeffrey M ClarkeNishan TchekmedyianJonathan Wade GoldmanSzu-Yun LeuGajanan BhatFrancois LebelJohn Victor HeymachMark A SocinskiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC.